Carna Biosciences, Inc. (TYO:4572)
Japan · Delayed Price · Currency is JPY 328.00
+13.00 (4.13%)
At close: Mar 6, 2026
Carna Biosciences Revenue
In the year 2025, Carna Biosciences had annual revenue of 579.06M JPY, down -8.95%. Carna Biosciences had revenue of 183.63M in the quarter ending December 31, 2025, with 23.42% growth.
Revenue
579.06M
Revenue Growth
-8.95%
P/S Ratio
10.87
Revenue / Employee
9.19M
Employees
63
Market Cap
6.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 579.06M | -56.94M | -8.95% |
| Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
| Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
| Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
| Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Linical | 9.32B |
| Kohjin Bio | 5.07B |
| Soiken Holdings | 4.58B |
| CellSource | 3.71B |
| PRISM BioLab Co.,LTD | 684.61M |
| Chiome Bioscience | 593.29M |
| D. Western Therapeutics Institute | 387.62M |
| ADR120S | 40.00M |